

## PERSONAL INFORMATION

### Tommaso Porcelli

📍 University of Naples Federico II  
Department of Public Health  
Address via S. Pansini 5, 80131, Naples, Italy

☎ +39 0817464520 📠 +39 3397639462

✉ [tommaso.porcelli@unina.it](mailto:tommaso.porcelli@unina.it)

## WORK EXPERIENCE

2021-present

### Assistant Professor of Endocrinology

Department of Public health, University of Naples Federico II, Naples, Italy.

- Research and clinical activities

Thyroid cancer diagnosis and treatment, peripheral thyroid hormones metabolism

2019-2021

### Post-doc fellowship

Department of Public health, University of Naples Federico II, Naples, Italy.

- Research and clinical activities

Thyroid cancer diagnosis and treatment, peripheral thyroid hormones metabolism

## EDUCATION AND TRAINING

2019

### Ph.D in Surgical and Biomedical Advanced Therapies

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

- Thyroid Cancer and peripheral thyroid hormones metabolism

2015

### Specialization in Endocrinology and Metabolic Diseases with full marks and laude

University of Rome La Sapienza, Rome, Italy.

- Thyroid peripheral thyroid hormones metabolism

2009

### M.D. degree with full marks and laude

University of Rome La Sapienza, Rome, Italy.

- Medicine and Surgery

## ADDITIONAL INFORMATION

### Publications

Salvatore D, Porcelli T, Ettleson M, Bianco AC. The relevance of T3 in the management of hypothyroid patients. *Lancet Diabetes and Endocrinology*. 2022 Feb;8

M Nacchio, P Pisapia, F Pepe, G Russo, E Vigliar, T Porcelli, C Luongo, et al. Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions *Expert Review of Endocrinology & Metabolism*. Volume 17, 2022 - Issue 2

C Luongo, T Porcelli, F Sessa, MA De Stefano, F Scavuzzo, V Damiano et al. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. *Current Oncology* 28 (6), 5401-5407

MA De Stefano, R Ambrosio, T Porcelli, G Orlandino, D Salvatore, C Luongo. Thyroid Hormone Action in Muscle Atrophy. *Metabolites* 11 (11), 730

Luongo, R Morra, C Gambale, T Porcelli, F Sessa, E Matano, V Damiano, M Klain, M Schlumberger, D Salvatore. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. *Journal of Endocrinological Investigation*. Jan 2020.

T Porcelli, C Luongo, F Sessa, M Klain, S Masone, G Troncone, C Bellevicine, M Schlumberger, D Salvatore. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. *Endocrine*. Jan 2020.

C Giani, L Valerio, A Bongiovanni, C Durante, G Grani, T Ibrahim, S Mariotti, M Massa, F Pani, G Pellegriti, T Porcelli, D Salvatore, M Tavarelli, M Torlontano, L Locati, E Molinaro, R Elisei. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. *Thyroid*. 2020 Oct 22.

A Nappi, E Di Cicco, C Miro, A Gaetana Cicatiello, S Sagliocchi, G Mancino, R Ambrosio, C Luongo, D Di Girolamo, MA De Stefano, T Porcelli, M Stornaiuolo, M Dentice. The NANOG transcription factor induces type 2 deiodinase expression and regulates the intracellular activation of thyroid hormone in keratinocyte carcinomas. *Cancers*, 2020, 12(3), 715.

Tommaso Porcelli and Domenico Salvatore. Targeting the right population for T3 + T4 combined therapy: where are we now and where to next? *Endocrine*, 2020, 69(2)

G Mancino, A Sibilio, C Luongo, E Di Cicco, C Miro, AG Cicatiello et al. The thyroid hormone inactivator enzyme, type 3 deiodinase, is essential for coordination of keratinocyte growth and differentiation. *Thyroid* 30 (7), 1066-1078

T Porcelli, F Sessa, C Gambale, C Luongo, D Salvatore. Management of one patient with oligoprogessive thyroid cancer during treatment with lenvatinib. *Future Oncology* 15 (24s), 21-25

Porcelli T, Sessa F, Luongo C and Salvatore D. Local ablative therapy for oligoprogessive TKI-treated thyroid cancer. *Journal of Endocrinological Investigation*, 2019 Gen 9.

Porcelli T, Sessa F, Caputo A, Catalini C and Salvatore D. Teriparatide Replacement Therapy for Hypoparathyroidism During treatment With Lenvatinib for advanced thyroid Cancer: a Case Report. *Frontiers in Endocrinology*, 2018 May 17

Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C, Garbi C, Pacini F and Salvatore D. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. *Journal of Clinical Endocrinology and Metabolism*, 2017 Feb 2

Miro C, Ambrosio R, De Stefano MA, Di Girolamo D, Di Cicco E, Cicatiello AG, Mancino G, Porcelli T, Raia M, Del Vecchio L, Salvatore D, Dentice M. The concerted action of type 2 and type 3 deiodinases regulates the cell cycle and survival of basal cell carcinoma cells. *Thyroid*. 2017 Jan 15

Di Girolamo D, Ambrosio R, De Stefano MA, Mancino G, Porcelli T, Luongo C, Di Cicco E, Scalia G, Vecchio LD, Colao A, Dlugosz AA, Missero C, Salvatore D, Dentice M. Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. *Journal of Clinical Investigation*, Jun 2016

Sciacchitano S, Lavra L, Ulivieri A, Magi F, Porcelli T, Amendola S, De Francesco GP, Bellotti C, Trovato MC, Salehi LB, Bartolazzi A. Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules. *Endocrine*, Oct 2015